New Grant for IAS Alumni Fellow Angela Casini

News |


Angela Casini

The German Research Foundation (DFG) will fund a new Collaborative Research Center led by the Technical University of Munich (TUM):

Transregio 387 will focus on how the ubiquitin system can be used for cancer therapies. The TRR UbiQancer aims to find new approaches for the treatment of selected tumor diseases through a better understanding of the role of the ubiquitin system in cancer.

Angela Casini, Professor for Medicinal and Bioinorganic Chemistry at TUM and IAS Hans Fischer Senior Alumni Fellow, and PI in the new project, says: “UbiQancer will boost the drug discovery pipeline via establishing the necessary synergies amongst the involved research centers. Our group is proud to represent the TUM medicinal chemistry community in the network. The project’s preparation has already impacted our research towards the development of innovative gold-based proteolysis targeting chimeras (PROTACs) as anticancer treatments,”.

UbiQancer is in the scope of the new TUM Center for Smart Drug Design (CSDD).

Read more: DFG approves Transregio UbiQancer TRR 387 - TUM School of Natural Sciences